Mumbai: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organisation, has been recognised as a leader for the fourth consecutive time in the IDC MarketScape for Worldwide Life Science R&D ITO Services 2018.1
According to the report, TCS received high marks for its technical skills, deep industry knowledge, competent end-to-end project delivery capabilities and ability to take greater project responsibility as more of a partner than a vendor. TCS’s strong technical focus, success with prominent life science companies and broad service offerings were also highlighted as strengths.
“Life sciences companies are embracing emerging technologies to reinvent their R&D processes to meet the challenge of evolving business models, higher R&D costs, elongated drug approval timelines and increasingly complex regulations,” said Debashis Ghosh, president, life sciences and healthcare, TCS. “This recognition of our leadership is a validation of our customer centricity and Business 4.0 vision that have been driving our investments in capabilities and future-ready solutions that are closely aligned to customer needs.”
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next-generation platforms and emerging technologies. TCS offers a full set of services spanning advisory, digital transformation and cognitive business operations in areas such as digitisation of clinical trials, paperless and integrated lab environment, Blockchain-enabled clinical supply chain, AI-enabled case processing and discovery collaboration. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, Internet of Things and cloud to fully digitise life sciences value chain.
TCS’s genomics and translational research offerings also deliver differentiated value to life sciences companies by combining bioinformatics analysis and DNA sequencing lab capabilities for emerging genomics-driven R&D initiatives.
“Life science companies are looking to harness the power of new technologies to reimagine their R&D processes. With its Business 4.0™ thought leadership framework, depth in life sciences-specific technologies, scale in digital and innovative offerings like the advanced drug development platform, TCS is well positioned to meet the transformation needs of its customers,” said Alan S Louie, research director, IDC Health Insights Life Science R&D Strategies and Technology.
“Our investments in digital solutions, vast industry and technical knowledge, along with our broad digital capabilities, services and platforms positions us as the preferred IT partner for our customers in the life sciences industry,” added Debashis Ghosh.